Derek Miller - 14 Mar 2022 Form 3 Insider Report for AMGEN INC (AMGN)

Role: SVP, Human Resources
Signature: /s/ Derek Miller
Issuer symbol: AMGN
Transactions as of: 14 Mar 2022
Net transactions value: $0
Form type: 3
Filing time: 17 Mar 2022, 19:00:05 UTC
Next filing: 22 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMGN	Common Stock						5,843	14 Mar 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMGN	Nqso (Right to Buy)							14 Mar 2022	Common Stock	1,524	$156.35	Direct	F3
holding	AMGN	Nqso (Right to Buy)							14 Mar 2022	Common Stock	2,069	$162.60	Direct	F4
holding	AMGN	Nqso (Right to Buy)							14 Mar 2022	Common Stock	1,821	$177.46	Direct	F5
holding	AMGN	Nqso (Right to Buy)							14 Mar 2022	Common Stock	3,692	$177.31	Direct	F6
holding	AMGN	Nqso (Right to Buy)							14 Mar 2022	Common Stock	3,365	$236.36	Direct	F7
holding	AMGN	Nqso (Right to Buy)							14 Mar 2022	Common Stock	3,405	$239.64	Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 81 RSUs which will vest on 4/27/2022; 614 RSUs which will vest on 4/27/2022; 283 RSUs which vest in installments of 139 on 5/3/2022 and 144 on 5/3/2023; 401 RSUs which vest in two installments of 132 on 5/5/2022 and 5/5/2023 and one installment of 137 on 5/5/2024; 392 RSUs which vest in two installments of 129 on 4/30/2023 and on 4/30/2024 and 134 on 4/30/2025; and 350 RSUs which vest in two installments of 175 on 11/5/2022 and 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2	These shares include 157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F3	1,524 of these non-qualified stock options have vested and are exercisable.
F4	2,069 of these non-qualified stock options have vested and are exercisable.
F5	1,201 of these non-qualified stock options have vested and are exercisable and 620 of these options will vest and become exercisable on 4/27/2022.
F6	1,218 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 1,218 on 5/3/2022 and 1,256 on 5/3/2023.
F7	These non-qualified stock options will vest and become exercisable in two installments of 1,110 on 5/5/2022 and 5/5/2023 and one installment of 1,145 on 5/5/2024.
F8	These non-qualified stock options will vest and become exercisable in three installments of 1,123 on 4/30/2023, 1,124 on 4/30/2024 and 1,158 on 4/30/2025.